Learn from every patient with CancerLinQ Discovery®

Improving clinical outcomes and achieving health equity depend on learning from the experiences of every patient with cancer. CancerLinQ Discovery® sits at the forefront of cancer research, giving you access to richly curated, de-identified patient data drawn from an industry-leading network of participating cancer centers and oncology practices. This powerful database can reveal new knowledge based on unseen trends and patterns in clinical practice—shaping the future of cancer care.

Researchers are using CancerLinQ Discovery data to do important work in cancer research

- Compare the effectiveness and value of alternative treatment options.
- Study the use of cancer treatments in populations typically excluded from clinical trials due to comorbidities or access challenges, to generate new knowledge to improve care.
- Assess the natural history of both rare and common cancer types across populations.
- Inform health disparities research and surveillance.
- Provide clinical trial design and feasibility analyses.
- Contribute to post-market safety and label expansion studies.
- Deliver insights to inform and continuously revise practice guidelines and quality measures.
- Provide training datasets for AI model development.
CancerLinQ Discovery includes comprehensive, longitudinal de-identified patient data from diverse clinical settings, including urban and rural community practices, academic hospitals, and major health systems.

Industry Leading Oncology Real-World Database

- Total patient records: 6M+
- Care sites across 100+ organizations: 800+
- Providers: 4K+
- Average longitudinal follow up time per patient: 4.5Y
- Integrated data sources: 20+

CancerLinQ is proud to offer CancerLinQ Discovery datasets across a growing number of tumor types including the following:

- Pan-Cancer
- Lung
- Breast
- Prostate
- Bladder
- Colorectal
- Pancreas
- Kidney/Renal Pelvis
- Multiple Myeloma
- Ovarian
- CLL-SLL

CancerLinQ Discovery data is de-identified as to patients and providers. © 2023 CancerLinQ LLC

For more information on CancerLinQ Discovery, email info@cancerling.org.
CancerLinQ Discovery® provides access to a comprehensive deidentified data asset reflecting the longitudinal healthcare experiences of patients with the full range of malignant neoplasms, both solid tumors and heme malignancies. This rich database provides a wealth of insights that enables your business strategy through generating robust real-world evidence.

**Key Stats**

- **6M+** Total patient records
- **20+** Data sources (10 EHRs, 10 secondary systems)
- **4.5Y** Average follow-up
- **3M+** Patients with cancer
- **15B+** Total database interactions
- **50** US States with CancerLinQ patients
- **420K+** Records with deep curation
- **165K+** Clinical data elements captured
- **67** Median age at diagnosis

**Data Catalog**

- **Disease Description**
  - Site, histology, grade
  - Staging (TNM, other)
  - Tissue and circulating biomarkers

- **Visits**
  - Clinician
  - Infusion

- **Procedures**
  - Imaging
  - Interventions

- **Treatments**
  - Antineoplastic medications and supportive medications
  - Radiation treatment
  - Surgery

- **Outcomes**
  - Adverse events
  - Reasons for treatment discontinuation
  - Therapeutic response
  - Vital status

- **Risk Factors**
  - Family history
  - Germline profiling
  - Alcohol and tobacco use
  - Pain and depression scores
  - Comorbidities
  - Other health problems and associated medications

- **Social Determinants of Health**

CancerLinQ Discovery data is de-identified as to patients and providers.
For more information on CancerLinQ Discovery, email info@cancerlinq.org.